All that 'talk' from the government amounted to not very much

July 27, 2020 Comment Latest News

This is a preview of subscriber content

Subscribe now to continue reading.

There was a lot of bluster from the federal government's during the negotiation and unsubtle threats about referring remuneration to the Pharmacy Benefits Remuneration Tribunal. …

Subscribe now to continue reading.

Latest Video

New Stories

'Patients can’t wait – swift action and access are the only possible moves from here'
August 26, 2025 - - Latest News
Vaxxas secures $90 million in funding to commercialise needle-free vaccination delivery technology
August 25, 2025 - - Australian Biotech
Bayer partners with Arrotex to strengthen access to oral contraceptives
August 25, 2025 - - Latest News
The next negotiation was always going to be complicated, the new reality will make it more so
August 25, 2025 - - Latest News
UK industry cites US pricing ambitions in collapse of new agreement negotiation
August 25, 2025 - - Latest News
Botanix appoints Dr Patricia Walker as a non-executive director
August 25, 2025 - - Australian Biotech
First site initiated for Neuren’s Phelan-McDermid syndrome Phase 3 trial
August 25, 2025 - - Australian Biotech

All that 'talk' from the government amounted to not very much

This is a preview of subscriber content

Latest Video

Most Read

UK industry cites US pricing ambitions in collapse of new agreement negotiation

PBAC delivers recommendations dominated by price cuts and risk shares

The next negotiation was always going to be complicated, the new reality will make it more so

'Patients can’t wait – swift action and access are the only possible moves from here'

Bayer partners with Arrotex to strengthen access to oral contraceptives

New Stories

'Patients can’t wait – swift action and access are the only possible moves from here'

Vaxxas secures $90 million in funding to commercialise needle-free vaccination delivery technology

Bayer partners with Arrotex to strengthen access to oral contraceptives

The next negotiation was always going to be complicated, the new reality will make it more so

UK industry cites US pricing ambitions in collapse of new agreement negotiation

Botanix appoints Dr Patricia Walker as a non-executive director

First site initiated for Neuren’s Phelan-McDermid syndrome Phase 3 trial

Sign In

All that 'talk' from the government amounted to not very much

This is a preview of subscriber content

Latest Video

Most Read

UK industry cites US pricing ambitions in collapse of new agreement negotiation

PBAC delivers recommendations dominated by price cuts and risk shares

The next negotiation was always going to be complicated, the new reality will make it more so

'Patients can’t wait – swift action and access are the only possible moves from here'

Bayer partners with Arrotex to strengthen access to oral contraceptives

Follow Us

New Stories

'Patients can’t wait – swift action and access are the only possible moves from here'

Vaxxas secures $90 million in funding to commercialise needle-free vaccination delivery technology

Bayer partners with Arrotex to strengthen access to oral contraceptives

The next negotiation was always going to be complicated, the new reality will make it more so

UK industry cites US pricing ambitions in collapse of new agreement negotiation

Botanix appoints Dr Patricia Walker as a non-executive director

First site initiated for Neuren’s Phelan-McDermid syndrome Phase 3 trial